ArticleAIDS and behavior2026
Biopsychosocial Factors' Influence on PrEP-uptake Among Danish MSM.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-exposure prophylaxis (PrEP) is an antiretroviral treatment aimed at reducing the risk of acquiring HIV. PrEP is a particularly important preventative measure for men who have sex with men (MSM), as they account for 21% of new global HIV cases despite being a small percentage of the population. In Denmark, over 50% of the total HIV cases involve MSM, despite MSM only accounting for 5-10% of the total population. MSM face higher HIV transmission risks due to factors such as engaging in unprotected anal intercourse. In 2019, PrEP became available in Denmark, and by 2022 there were approximately 2000 users. Despite free access, PrEP uptake remains low, with a relatively small share of eligible MSM estimated to be using it. Research into barriers to PrEP willingness among MSM is needed to improve uptake. An online cross-sectional survey was conducted from April to May 2024 to investigate biopsychosocial factors that may influence PrEP uptake among Danish MSM. Participants (N = 210) were recruited via LGBT+-specific social media forums and Danish AIDS Foundation clinics. Logistic regression models were used to analyze the data. The analysis showcased that non-users of PrEP, compared to users of PrEP, had 2.02 (CI: 1.10-3.70) times greater odds of experiencing a high stigmatization in the healthcare system and 5.73 (CI: 2.80-11.69) times greater odds of having a high fear of side-effects of PrEP. Out of the 104 non-user participants 40% were eligible for receiving PrEP-treatment fulfilling the Danish treatment specific risk criteria. When investigating non-users' willingness to undergo PrEP-treatment, the results showed that non-users with a high fear of side effects had 2.00 (CI: 1.10-4.40) times greater odds of showing high PrEP willingness and non-users with a high self-assessed risk of HIV had 5.60 (CI: 2.00-15.40) times greater odds of having high PrEP willingness compared to non-users who assess themselves as at low risk. These results indicate that biopsychosocial factors such as fear of side effects, self-assessed risk of HIV, and stigmatization in the healthcare system may influence non-users' uptake and withholding their willingness to seek PrEP-treatment. Biopsychosocial factors such as fear of side effects, self-perceived HIV risk, and healthcare-related stigma influence PrEP uptake among non-users. Effective public health interventions targeting these barriers are needed to increase uptake.
Indexed as
Identifiers
41422442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.